Search Results

New research reveals that combining two immunotherapy drugs has significantly boosted long-term survival rates for advanced melanoma patients

Virtually all cutaneous melanomas display genetic alterations that activate a cancer-driving pathway called MAPK. There is currently no FDA-approved options for treatment with MAPK-targeted drugs.

Circulating tumor DNA (ctDNA) is emerging as a blood-based biomarker for many solid tumor types, including melanoma

A new key mechanism has been identified behind the resistance of melanoma to BRAF inhibitors.

The risk of developing melanoma, a potentially deadly skin cancer, increases with age, men are more at risk than women

When it comes to skin cancer, most people think of warnings about sunburn and tanning beds.